Alladapt Immunotherapeutics
Latest round
- Series D
Last raised
- Jun 2022
Total raised
- $178M
Investors
- 7
About Alladapt Immunotherapeutics
Founded in 2018 in Menlo Park, California, Alladapt Immunotherapeutics, Inc. is dedicated to creating breakthrough therapies for allergy treatment.00 mn from Hercules Capital on August 30, 2022.Alladapt Immunotherapeutics specializes in immunotherapeutic products aimed at treating allergic conditions. Their key offerings include novel therapies designed to modulate the immune system's response to allergens, providing a potential solution for patients with allergic diseases.The company generates its revenue through the commercialization of its immunotherapy products, which are sold directly to healthcare providers and institutions. By establishing partnerships with key stakeholders in the healthcare industry, Alladapt aims to facilitate wider accessibility to its therapies, driving revenue growth as demand for effective allergy treatments increases. The company aims to introduce new therapies within the next 18 months, targeting specific allergic conditions that currently have limited treatment options. Additionally, they are exploring opportunities for expansion into international markets, particularly Europe and Asia, by 2024, to broaden their reach and impact in the global healthcare landscape.
Who invested in Alladapt Immunotherapeutics
7 investors across 2 rounds
See all investors in Alladapt Immunotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alladapt Immunotherapeutics
Who invested in Alladapt Immunotherapeutics?
Alladapt Immunotherapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alladapt Immunotherapeutics raised?
Alladapt Immunotherapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alladapt Immunotherapeutics last raise money?
Alladapt Immunotherapeutics's most recent round on record is a Series D, in Jun 2022.
What does Alladapt Immunotherapeutics do?
Founded in 2018 in Menlo Park, California, Alladapt Immunotherapeutics, Inc.
Where is Alladapt Immunotherapeutics headquartered?
Alladapt Immunotherapeutics is headquartered in Menlo Park, US.
Which VCs invest in companies like Alladapt Immunotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Alladapt Immunotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Alladapt Immunotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.